Pharmaceutical News

RSS

Marken to deliver clinical trial drugs in Korea during MERS outbreak

Marken, the leading clinical trial logistics organization providing solutions and services to the life sciences industry, has been granted permission by the government to deliver the first direct to patient shipment of clinical drug product in Korea.

30 Jun 2015

Egalet reports top-line results from Category 3 HAL study of Egalet-002

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced top-line results from a Category 3 human abuse liability (HAL) study of Egalet-002, an abuse-deterrent, extended-release, oral oxycodone product candidate in late-stage clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.

30 Jun 2015

New study examines how reasons for illicit marijuana use relate to use of other drugs

Marijuana is the most prevalent drug in the U.S. Approximately 70% of the 2.8 million individuals who initiated use of illicit drugs in 2013 reported that marijuana was their first drug.

30 Jun 2015

Improved medicine packaging designs increase caregivers' willingness to provide ORS to children

The usage of key medicines in developing countries could be significantly increased through improved packaging appearance, a new study by the Clinton Health Access Initiative, Inc. (CHAI) and the University of Warwick finds.

30 Jun 2015

Wistar Institute study shows that PI3K inhibitors may make a patient's cancer even worse

The enzyme phosphatidylinositol-3 kinase (PI3K) appears to be exploited in almost every type of human cancer, making it the focus of considerable interest as a therapeutic target, with many PI3K-inhibiting drugs currently in various stages of clinical development. However, PI3K inhibitors have only shown modest clinical activity with patients who receive these drugs experiencing very little improvement in survival.

30 Jun 2015

Government of the Republic of Equatorial Guinea to sponsor development of Sanaria PfSPZ Vaccine for malaria

The Government of the Republic of Equatorial Guinea announced an agreement with industry partners, Marathon Oil Corporation, Noble Energy Inc. and AMPCO, to sponsor the clinical development of Sanaria PfSPZ Vaccine against malaria, including a series of clinical trials from 2015 until 2018.

30 Jun 2015

Study may predict which glioblastoma patients may respond well to dasatinib drug treatment

Clinicians testing the drug dasatinib, approved for several blood cancers, had hoped it would slow the aggressive growth of the deadly brain cancer glioblastoma; however, clinical trials to date have not found any benefit. Researchers at Mayo Clinic, who conducted one of those clinical trials, believe they know why dasatinib failed — and what to do about it.

30 Jun 2015

SLU's Center for Vaccine Development receives $2.9 million to study new vaccine to combat TB

Saint Louis University's Center for Vaccine Development has received a $2.9 million award from the Bill & Melinda Gates Foundation to study a new tuberculosis vaccine.

30 Jun 2015

Two antibodies show early promise in preventing and treating MERS

As the South Korean epidemic of Middle East Respiratory Syndrome (MERS) continues unabated, researchers have raced to find treatments for the deadly virus, which has killed more than 400 people since it was first discovered three years ago in Saudi Arabia.

30 Jun 2015

Amphetamine-based drug Evekeo effective in treating ADHD symptoms in children

The amphetamine-based drug Evekeo, given once or twice daily to children 6-12 years of age, is effective in treating attention-deficit/hyperactivity disorder (ADHD) symptoms and improving performance in a laboratory classroom setting, according to the results of a new study published in the Journal of Child and Adolescent Psychopharmacology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

30 Jun 2015

Tris, Pfizer Consumer Healthcare sign agreement to market extended-release Robitussin for treatment of cough

Tris Pharma, Inc. today announced that it has entered into a license, supply, and distribution agreement with Pfizer Consumer Healthcare.

29 Jun 2015

Global GBM therapeutics market to expand at CAGR of 10.9% to $623 million by 2020

According to analysis from business intelligence provider GBI Research - Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2020 - the value of the global Glioblastoma Multiforme (GBM) treatment market will expand at a rapid Compound Annual Growth Rate (CAGR) of 10.9%, from $301 million in 2013 to $623 million by 2020.

29 Jun 2015

Can-Fite reports further progress in continuing preclinical program of CF602 sexual dysfunction drug

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported further progress in its continuing preclinical program of its CF602 drug candidate as the Company prepares to file an investigational new drug (IND) application with the U.S. Food and Drug Administration to allow the initiation of a Phase I clinical study.

29 Jun 2015

Egalet reports positive results from Category 3 abuse-deterrent intranasal HAL study

Egalet Corporation today announced positive results from a Category 3 intranasal human abuse liability (HAL) study of Egalet-001, an abuse-deterrent, extended-release, oral morphine formulation in late-stage clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.

29 Jun 2015

Cosmederm Bioscience expands TriCalm's line of anti-itch products to further benefit sufferers of itch

Cosmederm Bioscience, Inc. today announced the expansion of its itch-relief product line, TriCalm, with the new TriCalm Clinical Repair Cream and TriCalm Extra Strength Spray. Following the success of the company's initial product, TriCalm Hydrogel, these two new offerings strategically expand the brand's line of steroid-free, anti-itch products to further benefit sufferers of itch.

29 Jun 2015

Spinifex Pharmaceuticals enters into agreement to be acquired by Novartis

Spinifex Pharmaceuticals, Inc., a company focused on the development of new drugs for the treatment of chronic pain, today announces that it has agreed to the sale of Spinifex to Novartis International AG, for an upfront cash consideration of US$200 million plus undisclosed clinical development and regulatory milestone payments.

29 Jun 2015

Artemisinin and the fight against malaria: an interview with Dr. Robert Sebbag, Sanofi

Since 2014, more than 16 million anti-malarial treatments derived from the Sanofi patented process for semi-synthetic artemisinin have been supplied to endemic countries in Africa.

From Sanofi 28 Jun 2015

Adding tamper resistant properties to medications can help curb prescription drug abuse

Health Canada today published a Notice of Pre-Consultation in Canada Gazette, Part I, seeking stakeholder feedback on draft Tamper-Resistant Properties of Drugs Regulations.

27 Jun 2015

Study identifies effective market research approaches for understanding payer decision-making

The U.S. Supreme Court's ruling this week in support of the Affordable Care Act was good news for the health insurance industry. If the court had ruled against the government, insurers were at risk of losing millions of customers.

27 Jun 2015

Study suggests link between fatalistic beliefs and completion of HPV vaccine series among Appalachian women

Could a fatalistic attitude toward cervical cancer serve as a barrier to prevention of the disease? A recent study conducted by University of Kentucky researchers in the Rural Cancer Prevention Center suggests a link between fatalistic beliefs and completion of the human papillomavirus (HPV) vaccine series among a sample of young Appalachian Kentucky women.

27 Jun 2015

Pharmaceutical News

Marken to deliver clinical trial drugs in Korea during MERS outbreak

Egalet reports top-line results from Category 3 HAL study of Egalet-002

New study examines how reasons for illicit marijuana use relate to use of other drugs

Improved medicine packaging designs increase caregivers' willingness to provide ORS to children

Wistar Institute study shows that PI3K inhibitors may make a patient's cancer even worse

Government of the Republic of Equatorial Guinea to sponsor development of Sanaria PfSPZ Vaccine for malaria

Study may predict which glioblastoma patients may respond well to dasatinib drug treatment

SLU's Center for Vaccine Development receives $2.9 million to study new vaccine to combat TB

Two antibodies show early promise in preventing and treating MERS

Amphetamine-based drug Evekeo effective in treating ADHD symptoms in children

Tris, Pfizer Consumer Healthcare sign agreement to market extended-release Robitussin for treatment of cough

Global GBM therapeutics market to expand at CAGR of 10.9% to $623 million by 2020

Can-Fite reports further progress in continuing preclinical program of CF602 sexual dysfunction drug

Egalet reports positive results from Category 3 abuse-deterrent intranasal HAL study

Cosmederm Bioscience expands TriCalm's line of anti-itch products to further benefit sufferers of itch

Spinifex Pharmaceuticals enters into agreement to be acquired by Novartis

Artemisinin and the fight against malaria: an interview with Dr. Robert Sebbag, Sanofi

Adding tamper resistant properties to medications can help curb prescription drug abuse

Study identifies effective market research approaches for understanding payer decision-making

Study suggests link between fatalistic beliefs and completion of HPV vaccine series among Appalachian women

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News